 DURHAM, N.C.--BUSINESS WIRE--Aerie Pharmaceuticals, Inc. NASDAQ: AERI, an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Benjamin F. McGraw, III, Pharm.D., Interim Executive Chairman and David A. Hollander, M.D., M.B.A., Chief RD Officer, will participate in a fireside discussion at the 